日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Ultra-high dose rate radiotherapy overcomes radioresistance in head and neck squamous cell carcinoma.

超高剂量率放射疗法克服了头颈部鳞状细胞癌的放射抗性

Li Hong-Shuai, Tang Ruo, Shi Hua-Shan, Qin Zi-Jian, Zhang Xiao-Yang, Sun Yun-Fei, Wei Zhi-Gong, Ma Chao-Fan, Yang Liu, Chen Ye, Liu Zhe-Ran, Zhu Li-Li, Yang Wen, Yang Li, Xu Ai-Ning, Zhang Zhuo, Liao Shu-Qing, Shi Jin-Shui, Deng Jian-Jun, He Xiao-Zhong, Peng Xing-Chen

Neoadjuvant tislelizumab with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-1): a phase 2 clinical trial.

替雷利珠单抗联合阿法替尼治疗局部晚期头颈部鳞状细胞癌(neoCHANCE-1):一项 2 期临床试验。

Wei Zhi-Gong, Chen Hui-Jiao, Wang De-Juan, Jiang Zheng, Pei Yi-Yan, Li Le-Yu, Wang Feng, Jin Jing, Liu Zhe-Ran, Chen Fei, Liu Jun, Peng Xing-Chen

Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: a single-arm phase 2 trial

卡瑞利珠单抗联合阿帕替尼治疗既往接受过治疗的晚期肾上腺皮质癌:一项单臂 II 期试验

Zhu, Yu-Chun; Wei, Zhi-Gong; Wang, Jing-Jing; Pei, Yi-Yan; Jin, Jing; Li, Dong; Li, Zhi-Hui; Liu, Zhe-Ran; Min, Yu; Li, Rui-Dan; Yang, Li; Liu, Ji-Yan; Wei, Qiang; Peng, Xing-Chen